Search results
Antoni Martínez-Rubio
Research Area(s) / Expertise:
Author
Author(s):
Neal W White Jr
Added:
3 years ago
Hospital to Home (H2H) is a national quality improvement initiative of the American College of Cardiology (ACC) and the Institute for Healthcare Improvement (IHI). It builds on the success of the ACC Door-to-Balloon Alliance for Quality and the IHI 100K Lives and 5 Million Lives campaigns. The goal of the H2H initiative is to reduce 30-day all-cause readmission rates for patients discharged with…
View more
Author(s):
Xiao-Fei Gao
,
Xiang-Quan Kong
,
Guang-Feng Zuo
,
et al
Added:
3 years ago
Coronary angiography is widely used to diagnose coronary artery disease and to guide percutaneous coronary intervention (PCI). However, 2D projection angiography cannot completely reflect the 3D coronary lumen, with several inherent limitations in evaluating plaque composition, vessel diameter, diffuse reference vessel disease, lesion severity, as well as the result of stent deployment. In the…
View more
Author(s):
Sabu Thomas
,
Andrew J Boyle
,
Gary S Francis
Added:
3 years ago
Acute decompensated heart failure (ADHF) is a syndrome defined by worsening fatigue, dyspnea, or edema that results from deteriorating heart function and usually leads to hospital admission or unscheduled medical intervention.1 Among patients over 65 years of age it remains the leading cause of hospital admission (>1 million admissions per year in the US alone), has an exceptionally high rate…
View more
Author(s):
Victor L Serebruany
Added:
3 years ago
Understanding of the pathogenesis of congestive heart failure (CHF) has improved remarkably in recent years. However, despite better knowledge and novel pharmaceutical strategies, this disease is still one of the most brutal killers in the Western world. The pathophysiology of CHF is complex, and much of our comprehension revolves strictly around the neurohormonal and mechanical mechanisms…
View more
Author(s):
Lorenz Räber
Added:
1 year ago
In this late-breaking interview focusing on the PACMAN-AMI Trial, Prof Lorenz Räber (Bern University Hospital, CH) reveals that the use of alirocumab reduced coronary plaque regression in patients with acute myocardial infarction (AMI) (NCT03067844).
Originally presented by Prof Raber at ACC.22, these findings suggest that alirocumab, on top of high-intensity statin therapy, may be an effective…
View more
Author(s):
Randall S Stafford
,
Veronica Monti
,
Jun Ma
Added:
3 years ago
Cardiovascular disease (CVD), including myocardial infarction and stroke, is the leading cause of morbidity and mortality in the US. A broad array of randomized trials have demonstrated the benefits of low doses of aspirin (75-325mg)1,2 for both the primary3-7 and secondary8-11 prevention of CVD. Most trials demonstrate a 15-40% reduction in cardiovascular events with chronic aspirin use.Aspirin…
View more
Author(s):
Randall S Stafford
,
Veronica Monti
,
Jun Ma
Added:
3 years ago
Cardiovascular disease (CVD), including myocardial infarction and stroke, is the leading cause of morbidity and mortality in the US. A broad array of randomized trials have demonstrated the benefits of low doses of aspirin (75-325mg)1,2 for both the primary3-7 and secondary8-11 prevention of CVD. Most trials demonstrate a 15-40% reduction in cardiovascular events with chronic aspirin use.Aspirin…
View more
Author(s):
David S Rosenbaum
Added:
3 years ago
Heart disease is the leading cause of death in the US with 700,000 deaths annually, of which 460,000 are attributable to sudden cardiac death (SCD).1,2 SCD is usually attributed to ventricular fibrillation (VF). Despite recent reductions in cardiac mortality from other causes, the incidence of SCD remains high with minimal decline in the last decade. The large majority of patients who suffer life…
View more
Added:
5 months ago
Source:
Radcliffe Cardiology
Find out what's hot at TCT in this preview from Prof Nicolas Van Mieghem and Dr Joost Daemen
The Cardiovascular Research Foundation (CRF) has unveiled the late-breaking clinical trials scheduled for presentation at the 2023 Transcatheter Cardiovascular Therapeutics (TCT) annual meeting taking place from October 23 to 26 in San Francisco. TCT is renowned for showcasing groundbreaking research in…
View more